EUVIMEDEUVIMED entdecken
Open Access

Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science

Danielle R Adams iD, Heidi Allen, Ginger E Nicol iD, Leopoldo J Cabassa iD

Translational Behavioral Medicine · 25.11.2024 · 14 (12) · 744-752

DOI: 10.1093/tbm/ibae053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Behavioral Medicine, online erschienen am 17.10.2024. Verfasst von Danielle R Adams und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Social Work, College of Health Sciences, University of Missouri-Columbia, Columbia, MO 65211, USA. Hauptthemen laut MEDLINE: Hallucinogens, Implementation Science, Psychotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, Usona Institute, Steven and Alexandra Cohen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the potential to produce rapid therapeutic effects when paired with psychotherapy. Randomized clinical trials of psychedelic-assisted psychotherapy (PAT) have shown promising results for post-traumatic stress disorder (PTSD), depression, and substance use disorders. The U.S. Food and Drug Administration has acknowledged the promise of PAT, signaling potential approval of psilocybin-assisted therapy for depression by 2026. Given this timeline, implementation scientists must engage with PAT researchers, policymakers, and practitioners to think critically about bringing these promising new treatments into routine practice settings while maintaining quality and safety. This commentary aims to initiate a dialogue between implementation scientists and PAT researchers and practitioners on addressing these questions with a lens toward equity. Specifically, we discuss how the field of implementation science can support PAT stakeholders to accelerate the translational process from research into practice, focusing specifically on safety-net settings (i.e., Federally Qualified Health Centers and Veterans Affairs health systems) that serve historically marginalized populations. We use the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) Framework to illustrate five critical areas where implementation science can help move PAT from research into real-world practice. For each RE-AIM dimension, we highlight ways the field of implementation science can contribute tools (e.g., implementation strategies), methodologies (e.g., pragmatic hybrid implementation-effectiveness trials), and approaches (community-based participatory research) for establishing the safety, effectiveness, and accessibility of PAT for historically underserved communities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensImplementation SciencePsychotherapyHumansStress Disorders, Post-TraumaticSubstance-Related DisordersUnited StatesDepressionPsilocybin

Stichwörter der Autor:innen

equityimplementation sciencemental healthpsilocybinpsychedelic-assisted therapysafety-net health settings

Substanzen

HallucinogensPsilocybin

Autor:innen und Institutionen

  • School of Social Work, College of Health Sciences, University of Missouri-Columbia, Columbia, MO 65211, USA.
  • School of Social Work, Colombia.
  • University, New York City, NY 10027, USA.
  • Department of Psychiatry, Washington University School of Medicine in St. Louis, MO 63110, USA.
  • Brown School of Social Work, Washington University in St. Louis, MO 63105, USA.
  • Center for Mental Health Services Research, Washington University in St. Louis, MO 63105, USA.

ORCID-Profile: Danielle R Adams, Ginger E Nicol, Leopoldo J Cabassa

Förderung

  • NIMH NIH HHS
  • Usona Institute
  • Steven and Alexandra Cohen Foundation
  • Alkermes, Inc
  • LB Pharmaceuticals, Inc.
  • COMPASS pathways
  • Joe and Sandy Samberg Foundation
  • NIDDK NIH HHS

Zitieren

APA

Adams, D. R., Allen, H., Nicol, G. E., & Cabassa, L. J. (2024). Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science. Translational Behavioral Medicine, 14(12), 744-752. https://doi.org/10.1093/tbm/ibae053

Vancouver

Adams DR, Allen H, Nicol GE, Cabassa LJ. Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science. Translational Behavioral Medicine. 2024;14(12):744-752. doi:10.1093/tbm/ibae053

BibTeX
@article{Adams2024,
  author = {Adams, Danielle R and Allen, Heidi and Nicol, Ginger E and Cabassa, Leopoldo J},
  title = {Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science},
  journal = {Translational Behavioral Medicine},
  year = {2024},
  volume = {14},
  number = {12},
  pages = {744--752},
  doi = {10.1093/tbm/ibae053}
}
Kostenlos starten →